Estimate 5-year and lifetime breast cancer risk using Gail Model factors: age, menarche, first birth, family history, biopsies, and atypical hyperplasia. Includes chemoprevention and screening guid...
The Gail Model (also known as the Breast Cancer Risk Assessment Tool, BCRAT) is the most widely used tool for estimating a woman's 5-year and lifetime risk of developing invasive breast cancer. Developed by Dr. Mitchell Gail and colleagues at the National Cancer Institute in 1989, it uses seven key risk factors: age, age at menarche, age at first live birth, number of first-degree relatives with breast cancer, number of prior breast biopsies, presence of atypical hyperplasia, and race/ethnicity.
The model's primary clinical application is identifying women eligible for chemoprevention. The NSABP P-1 trial established the 1.7% 5-year risk threshold for tamoxifen eligibility, while the STAR and MAP.3 trials validated raloxifene and aromatase inhibitors respectively. Women with ≥20% lifetime risk also qualify for enhanced screening with annual breast MRI per ACS guidelines.
This calculator provides an educational Gail-inspired risk estimate, comparison to population averages, chemoprevention eligibility assessment, and comprehensive screening guideline summaries from major organizations. For definitive clinical use, the official NCI BCRAT tool should be used.
The Gail Model is the standard breast cancer risk assessment tool used in clinical practice. This calculator provides accessible risk estimation, chemoprevention eligibility assessment, and personalized screening guideline recommendations. Keep these notes focused on your operational context. Tie the context to the calculator’s intended domain. Use this clarification to avoid ambiguous interpretation. Align this note with review checkpoints.
Gail Model estimates use relative risk multipliers for: - Age at menarche (earlier = higher risk) - Age at first live birth (later/nulliparous = higher risk) - First-degree relatives (each approximately doubles risk) - Prior biopsies (more biopsies = higher risk) - Atypical hyperplasia (~2× risk multiplier) - Race/ethnicity (different baseline incidence rates) 5-year risk = baseline incidence × combined relative risk Lifetime risk approximated from 5-year projection
Result: 5-year risk: ~3%.
A 50-year-old white woman with one affected first-degree relative, menarche at 12, first birth at 28, and no biopsies has a 5-year risk of approximately 3%. This exceeds the 1.7% threshold for chemoprevention eligibility. Discussion of tamoxifen or aromatase inhibitor risk/benefit is warranted.
The original Gail Model was published in 1989 and has undergone several updates. The most current version (BCRAT) includes race-specific hazard rates for White, African American, Hispanic, and Asian/Pacific Islander women. It has been validated in over 1 million women through the Breast Cancer Prevention Trial and Nurses' Health Study, confirming accurate population-level calibration.
Several models provide complementary risk assessment. The Tyrer-Cuzick (IBIS) model incorporates second-degree family history, BRCA status, mammographic density, and hormonal factors — providing better discrimination for high-risk women. BRCAPRO estimates BRCA mutation carrier probability. CanRisk (formerly BOADICEA) is the most comprehensive, integrating genetics, polygenic risk scores, and clinical factors into a single model.
Mammographic breast density is a strong, independent risk factor not captured by the original Gail Model. Women with extremely dense breasts (BI-RADS D) have 4-6 times higher risk than those with fatty breasts. Many states now mandate breast density notification, and supplemental screening (MRI, ultrasound, or contrast-enhanced mammography) is increasingly recommended for dense-breasted women at elevated risk.
The Gail Model is designed for women aged 35-85 without a personal history of breast cancer, ductal carcinoma in situ (DCIS), or lobular carcinoma in situ (LCIS). It is not appropriate for women with known BRCA mutations — they should use models like BRCAPRO or Tyrer-Cuzick.
The 1.7% threshold was chosen because it equals the 5-year risk of a 60-year-old average-risk woman, which was the eligibility criterion for the NSABP P-1 tamoxifen chemoprevention trial. Women at or above this threshold are candidates for chemoprevention.
No. The Gail Model does not incorporate genetic testing results. Women with strong family histories of breast/ovarian cancer (especially early-onset or bilateral) should be referred for genetic counseling and risk assessment with models that incorporate genetic data (BRCAPRO, Tyrer-Cuzick, CanRisk).
The Gail Model has good calibration (predicts the correct number of cancers in a population) but moderate discrimination (ability to distinguish who will develop cancer). Its C-statistic is approximately 0.58-0.62, meaning individual predictions have uncertainty. It performs best as a population screening tool rather than individual prediction.
The average US woman has approximately a 12.5% (1 in 8) lifetime risk of breast cancer. This includes all ages from birth to death. Risk varies significantly by decade — most breast cancers occur after age 50.
The decision is individualized based on risk-benefit analysis. Tamoxifen reduces invasive breast cancer by ~49% over 5 years but carries risks of venous thromboembolism, endometrial cancer, and hot flashes. For premenopausal women 35-50, the benefit generally outweighs risk. For postmenopausal women, aromatase inhibitors may be preferred.